Merck sends BACE advanced raiding party into corpse-littered Alzheimer's landscape
This article was originally published in Scrip
Executive Summary
Merck & Co is to take its BACE1 inhibitor MK-8931 into Phase II/III in Alzheimer's disease just days after yet another candidate, Bristol-Myers Squibb's avagacestat, was discontinued.
You may also be interested in...
Sanofi’s Sutimlimab Shows Promise In Rare Blood Disorder
A Phase III rare-disease hit for Sanofi marks the first of a number of orphan drug read-outs expected in the coming year.
Five Trials To Look Out For At The AHA Meeting
Philadelphia is due to host the American Heart Association (AHA) meeting for the first time from 16-18 November, with the conference taking place in its condensed three-day format for just the second time. Scrip takes a look at the expected highlights.
ObsEva Gives Up On IVF Drug As Phase III Study Fails
Shares plummet as ObsEva announces it is discontinuing its IVF program for nolasiban after disappointing Phase III data from a European confirmatory study.
Need a specific report? 1000+ reports available
Buy Reports